ArticleScientific reports2025
Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
High-grade astrocytomas vary in incidence and mortality across populations, with Hispanic and Latino groups largely underrepresented in genomic epidemiology studies. This study characterizes the presence of known mutations of high-grade astrocytomas in a Latin American cohort through targeted genomic analysis of 70 Chilean patients. Molecular markers, including IDH, TERTp, H3, TP53, PTEN, EGFR, and CDKN2A, were assessed alongside survival analyses. Our results mostly aligned with international cohorts, confirming the importance of established molecular markers in glioblastoma. Novel damaging TP53 and PTEN mutations were identified, expanding the genetic spectrum of known mutations for these genes, while a lower-than-expected NF1 mutation frequency was observed (p < 0.01). These findings highlight the importance of examining underrepresented populations, providing insights into the molecular characteristics of high-grade astrocytomas in Latin America. Our findings contribute to understanding the diversity of genomic features across astrocytoma populations, setting a foundation for future international comparative studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.